Cybin Inc. Common Stock (HELP) - Total Liabilities
Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has total liabilities worth $22.20 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore HELP cash flow metrics to assess how effectively this company generates cash.
Cybin Inc. Common Stock - Total Liabilities Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Cybin Inc. Common Stock (HELP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Cybin Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Cybin Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hyundai Corp
KO:011760
|
Korea | ₩2.04 Trillion |
|
Strike Energy Limited
F:RJN
|
Germany | €130.16 Million |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
Germany | €242.40 Million |
|
JS Corp
KO:194370
|
Korea | ₩1.28 Trillion |
|
Kaset Thai International Sugar Corporation Public Company Limited
BK:KTIS
|
Thailand | ฿8.41 Billion |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
USA | $120.49 Million |
|
Pruksa Holding Public Company Limited
BK:PSH
|
Thailand | ฿20.55 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Cybin Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cybin Inc. Common Stock stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cybin Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual total liabilities of Cybin Inc. Common Stock from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $21.42 Million | +112.14% |
| 2024-03-31 | $10.10 Million | +78.28% |
| 2023-03-31 | $5.66 Million | -28.39% |
| 2022-03-31 | $7.91 Million | +31.93% |
| 2021-03-31 | $5.99 Million | +2179.09% |
| 2020-03-31 | $263.00K | +1826.32% |
| 2019-03-31 | $13.65K | -14.30% |
| 2018-03-31 | $15.93K | -89.40% |
| 2017-03-31 | $150.29K | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more